MetaCap

Maze Therapeutics (MAZE) vs Recursion Pharmaceuticals (RXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maze Therapeutics (MAZE) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 13.5% versus a loss of 41.2%. Maze Therapeutics is the larger company by market cap ($1.72 billion vs $1.53 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MAZE-13.49%RXRX-41.25%
+47%+1%-45%
Nov 21, 20251 yearNov 20, 2026
MAZE+96.68%RXRX-66.16%
+229%+74%-80%
Jan 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MAZE versus RXRX key metrics
MetricMAZERXRX
Share price$31.37$2.45
Market cap$1.72B$1.53B
1-day change-3.27%-9.93%
YTD return-24.28%-40.10%
1-year return-13.49%-41.25%
5-year return—-87.04%
EPS (TTM)$-2.62$-0.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$74.68M
Revenue growth (YoY)—+26.92%
Net income (latest FY)$-131.12M$-644.76M
Gross margin—4.99%
Operating margin—-867.87%
Net margin—-863.35%
52-week high$53.65$5.24
52-week low$21.95$2.44
Distance from 52-week high-41.53%-53.24%
Analyst consensusstrong_buybuy
Avg. price target upside+99.11%+176.33%
Average volume737.14K24.47M
Shares outstanding54.68M622.76M
Employees141600
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MAZE has outperformed RXRX by 27.8 percentage points over the past year.

About Maze Therapeutics

MAZE stock →

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

MAZE vs RXRX FAQ

Which is bigger, Maze Therapeutics or Recursion Pharmaceuticals?

Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.72B compared with $1.53B for Recursion Pharmaceuticals (RXRX).

Which stock has performed better over the past year, MAZE or RXRX?

MAZE returned -13.49% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.

Are Maze Therapeutics and Recursion Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons